Advertisement
Ingenuity
Ingenuity

News Analysis

Most Recent

Nearly a million children die each year of malaria, but the parasite became resistant to the cheapest drug. Now we know why.

0 Comments

Modifying genetic research

By | November 15, 2000

GM food has provoked much protest but GM medicine has more public approval: the difference lies in approaches to research.

0 Comments

Many drugs effective against tropical diseases are no longer available or in danger of being pulled from the market because they are unprofitable.

0 Comments

Ritalin gets vote of approval in the UK

By | November 9, 2000

A new UK directive supports use of the controversial drug Ritalin in severe Attention Deficit/Hyperactivity Disorder (ADHD), but only under specialist supervision.

0 Comments

A game of monopoly

By | November 8, 2000

Reed Elsevier's proposed takeover of Harcourt has provoked an outcry from librarians and academics alike - but do they have the muscle to influence it?

0 Comments

Therapeutic cloning endorsed by Royal Society

By | November 8, 2000

The UK's Royal Society yesterday released a report backing continued research into the use of cloned embryonic stem cells.

0 Comments

HOUSTON. Amgen, the largest biotechnology company in the world, is funding research focusing on disorders that destroy parts of the nervous system. These include Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke. Medicines for disorders resulting from dysfunction of the neuroendocrine system such as obesity and Type 2 diabetes are also under development. In both areas, Amgen licenses product candidates and technologies that complement its internal drug discovery and develop

0 Comments

New companies to commercialise neuroscience discoveries

By | November 3, 2000

Neurogenomics has significant commercial potential by way of gene targets for enhancement of brain function and treatment of brain-based disease.

0 Comments

Senior scientists promise to boycott journals

By | November 2, 2000

Leading scientists will refuse to publish, edit or subscribe to journals that do not make research articles available free of charge.

0 Comments

BSE Inquiry out in the open

By | October 26, 2000

The results of the UK government's BSE Inquiry were published on Thursday 26 October, implicating civil servants and scientists in the health scandal.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
Ingenuity
Ingenuity

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
The Scientist
The Scientist
Life Technologies